Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
Sign Up to like & getrecommendations! Published in 2022 at "Healthcare"
DOI: 10.3390/healthcare11010072
Abstract: Introduction: secondary hyperparathyroidism (SHP) is frequent in patients with chronic kidney disease (CKD), particularly in those in dialysis. To treat this complication, the current options available include phosphorus restriction, phosphate binders, the inhibition of parathyroid… read more here.
Keywords: chronic kidney; paricalcitol; kidney disease; etelcalcetide paricalcitol ... See more keywords